Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions

American Journal of Dermatopathology

Volumn 30, Issue 2, 2008, Pages 117-122

  Nasr, Michel R ^a,b   El Zammar, Ola ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Ki 67; Malignant melanoma; Melanocytic nevi; PHH3; Survivin

Indexed keywords

KI 67 ANTIGEN; PROTEIN; PROTEIN PHH3; SURVIVIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL NUCLEUS; COMPOUND NEVUS; CYTOPLASM; DERMOEPIDERMAL JUNCTION; DIFFERENTIAL DIAGNOSIS; DYSPLASTIC NEVUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; JUVENILE MELANOMA; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; MICROSCOPY; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

ADOLESCENT; ADULT; AGED; BIOPSY, NEEDLE; CHI-SQUARE DISTRIBUTION; CHILD, PRESCHOOL; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KI-67 ANTIGEN; MALE; MELANOMA; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEVUS, EPITHELIOID AND SPINDLE CELL; NEVUS, PIGMENTED; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 41149122099     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181624054     Document Type: Article

References (33)

1. Schmoeckel C. How consistent are dermatopathologists in reading early malignant melanomas and lesions "precursor" to them? Am J Dermatopathol. 1984;6:13-24.
2. Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol. 1996;27:528-531.
3. Zembowicz A, McCusker M, Chairelli C. Morphological analysis of nevoid melanoma: a study of 20 cases with a review of the literature. Am J Dermatopathol. 2001;23:167-175.
4. Elder DE, Murphy GF. Atlas of Tumor Pathology: Melanocytic Tumors of the Skin. Washington, DC: Armed Forces Institute of Pathology; 1990.
5. Tran TA, Ross JS, Carlson JA, et al. Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions. Hum Pathol. 1998;29:1085-1090.
6. Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology. 2002;40:2-11.
7. Smolle J, Soyer HP, Kerl H. Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody. A quantitative immunohistochemical study. Am J Dermatopathol. 1989;11:301-307.
8. Rieger E, Hofmann-Wellenhof R, Soyer HP, et al. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study. J Cutan Pathol. 1993;20:229-236.
9. Rudolph R, Schubert C, Schubert B, et al. Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. J Am Acad Dermatol. 1997;37: 169-178.
10. Kanter L, Blegen H, Wejde J, et al. Utility of a proliferation marker in distinguishing between benign naevocellular naevi and naevocellular naevus-like lesions with malignant properties. Melanoma Res. 1995;5: 345-350.
11. Sparrow LE, English DR, Taran JM, et al. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. Am J Dermatopathol. 1998;20:12-16.
12. Kaleem Z, Lind A, Humphrey P, et al. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas? Mod Pathol. 2000;13:217-222.
13. Bergman R, Malkin L, Sabo E, et al. MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. J Am Acad Dermatol. 2001;44:500-504.
14. Li LX, Crotty KA, McCarthy SW, et al. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2000;22:489-495.
15. Moretti S, Massobrio R, Brogelli L, et al. Ki67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions. J Invest Dermatol. 1990;95:183.
16. Harvell JD, Bastian BC, LeBoit PE. Persistent (recurrent) Spitz nevi: a histopathologic, immunohistochemical, and molecular pathologic study of 22 cases. Am J Surg Pathol. 2002;26:654-661.
17. Soyer HP. Ki 67 immunostaining in melanocytic skin tumours. Correlation with histologic parameters. J Cutan Pathol. 1990;18:43-52.
18. Weedon D, Little JH. Spindle and epithelioid cell nevi in children and adults. Cancer. 1977;40:217-225.
19. Barnhill RL, Busam KJ. Pathology of melanocytic nevi and malignant melanoma. Boston, MA: Butterworth-Heinemann; 1995.
20. Crotty KA, McCarthy SW, Palmer AA, et al. Malignant melanoma in childhood: a clinicopathologic study of 13 cases and comparison with Spitz nevi. World J Surg. 1992;16:179-185.
21. Ribalta T, McCutcheon IE, Aldape KD, et al. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol. 2004;28:1532-1536.
22. Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113:1076-1081.
23. Gradilone A, Gazzaniga P, Ribuffo D, et al. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol. 2003;21:306-312.
24. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol. 2003;199:275-288.
25. Chiodino C, Cesinaro AM, Ottani D, et al. Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol. 1999;113:415-418.
26. Florell SR, Bowen AR, Hanks AN, et al. Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J Cutan Pathol. 2005;32:45-49.
27. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene. 2004;23:39-48.
28. Blanc-Brude OP, Mesri M, Wall NR, et al. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res. 2003;9: 2683-2692.
29. Wheatley SP, Carvalho A, Vagnarelli P, et al. INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol. 2001;11:886-890.
30. Skoufias DA, Mollinari C, Lacroix FB, et al. Human survivin is a kinetochore-associated passenger protein. J Cell Biol. 2000;151:1575-1582.
31. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580-584.
32. Grossman D, Kim PJ, Schechner JS, et al. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA. 2001;98: 635-640.
33. Ding Y, Prieto VG, Zhang PS, et al. Nuclear expression of the antiapoptotic protein survivin in malignant melanoma. Cancer. 2006; 106:1123-1129.